These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

964 related articles for article (PubMed ID: 9007946)

  • 1. p53 expression in uveal malignant melanomas.
    Jay V; Yi Q; Hunter WS; Zielenska M
    Pathology; 1996 Nov; 28(4):306-8. PubMed ID: 9007946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 Immunoreactivity, Ki-67 expression, and microcirculation patterns in melanoma of the iris, ciliary body, and choroid.
    Chowers I; Folberg R; Livni N; Pe'er J
    Curr Eye Res; 2002 Feb; 24(2):105-8. PubMed ID: 12187481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors.
    Mouriaux F; Maurage CA; Labalette P; Sablonnière B; Malecaze F; Darbon JM
    Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):2837-43. PubMed ID: 10967035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PC-10 immunostaining of proliferating cell nuclear antigen in posterior uveal melanoma. Enucleation versus enucleation postirradiation groups.
    Pe'er J; Gnessin H; Shargal Y; Livni N
    Ophthalmology; 1994 Jan; 101(1):56-62. PubMed ID: 7905616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KI-67 immunopositivity in choroidal and ciliary body melanoma with respect to nucleolar diameter and other prognostic factors.
    Al-Jamal RT; Kivelä T
    Curr Eye Res; 2006 Jan; 31(1):57-67. PubMed ID: 16421020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
    Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
    Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study.
    Pe'er J; Stefani FH; Seregard S; Kivela T; Lommatzsch P; Prause JU; Sobottka B; Damato B; Chowers I
    Br J Ophthalmol; 2001 Oct; 85(10):1208-12. PubMed ID: 11567966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of microcirculation patterns and MIB-1 immunoreactivity in iris and posterior uveal melanoma.
    Chowers I; Folberg R; Livni N; Pe'er J
    Ophthalmology; 2001 Feb; 108(2):367-71. PubMed ID: 11158814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki-67 immunostaining in uveal melanoma. The effect of pre-enucleation radiotherapy.
    Mooy CM; de Jong PT; Van der Kwast TH; Mulder PG; Jager MJ; Ruiter DJ
    Ophthalmology; 1990 Oct; 97(10):1275-80. PubMed ID: 2243677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microcirculation architecture of melanocytic nevi and malignant melanomas of the ciliary body and choroid. A comparative histopathologic and ultrastructural study.
    Rummelt V; Folberg R; Rummelt C; Gruman LM; Hwang T; Woolson RF; Yi H; Naumann GO
    Ophthalmology; 1994 Apr; 101(4):718-27. PubMed ID: 8152768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered expression of Rb and p53 in uveal melanomas following plaque radiotherapy.
    Brantley MA; Worley L; Harbour JW
    Am J Ophthalmol; 2002 Feb; 133(2):242-8. PubMed ID: 11812429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.
    Chorny JA; Barr RJ; Kyshtoobayeva A; Jakowatz J; Reed RJ
    Mod Pathol; 2003 Jun; 16(6):525-9. PubMed ID: 12808056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-myc oncogene expression in ocular melanomas.
    Royds JA; Sharrard RM; Parsons MA; Lawry J; Rees R; Cottam D; Wagner B; Rennie IG
    Graefes Arch Clin Exp Ophthalmol; 1992; 230(4):366-71. PubMed ID: 1505770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of PAX8 Immunohistochemistry in Adult Intraocular Tumor Diagnosis.
    Mudhar HS; Milman T; Eagle RC; Sanderson T; Pheasey L; Paine S; Salvi S; Rennie IG; Rundle P; Shields CL; Shields JA
    Ophthalmology; 2021 May; 128(5):765-778. PubMed ID: 33002562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of nucleolar organizer regions in uveal melanoma. The Collaborative Ocular Melanoma Study Group.
    Marcus DM; Minkovitz JB; Wardwell SD; Albert DM
    Am J Ophthalmol; 1990 Nov; 110(5):527-34. PubMed ID: 1700611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
    Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
    Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of bcl-2 in uveal malignant melanoma.
    Jay V; Yi Q; Hunter WS; Zielenska M
    Arch Pathol Lab Med; 1996 May; 120(5):497-8. PubMed ID: 8639055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative assessment of the blood-aqueous barrier in human eyes with malignant or benign uveal tumors.
    Küchle M; Nguyen NX; Naumann GO
    Am J Ophthalmol; 1994 Apr; 117(4):521-8. PubMed ID: 8154537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type.
    Paraoan L; Gray D; Hiscott P; Ebrahimi B; Damato B; Grierson I
    Exp Eye Res; 2006 Oct; 83(4):911-9. PubMed ID: 16784742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension?
    Heindl LM; Hofmann TN; Adler W; Knorr HL; Holbach LM; Naumann GO; Kruse FE; Cursiefen C
    Ophthalmology; 2010 Feb; 117(2):334-42. PubMed ID: 19892405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.